Abstract
In this issue of Blood, Sánchez-Martínez and colleagues present a novel approach to the treatment of T-acute lymphoblastic leukemia (T-ALL) using chimeric antigen receptor (CAR) T cells redirected against CD1a1 in in vitro and xenograft models.